Skip to main content
Log in

Rapid response to a single-dose rituximab combined with bortezomib in refractory and relapsed warm autoimmune hemolytic anemia

Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Barcellini W, Fattizzo B, Zaninoni A (2018) Current and emerging treatment options for autoimmune hemolytic anemia. Expert Rev Clin Immunol 10:857–872. https://doi.org/10.1080/1744666x.2018.1521722

    Article  CAS  Google Scholar 

  2. Dierickx D, Kentos A, Delannoy A (2015) The role of rituximab in adults with warm antibody autoimmune hemolytic anemia. Blood 21:3223–3229. https://doi.org/10.1182/blood-2015-01-588392

    Article  CAS  Google Scholar 

  3. Reynaud Q, Durieu I, Dutertre M et al (2015) Efficacy and safety of rituximab in auto-immune hemolytic anemia: a meta-analysis of 21 studies. Autoimmun Rev 4:304–313. https://doi.org/10.1016/j.autrev.2014.11.014

    Article  CAS  Google Scholar 

  4. Mohty M, Brissot E, Savani BN et al (2013) Effects of bortezomib on the immune system: a focus on immune regulation. Biol Blood Marrow Transplant 10:1416–1420. https://doi.org/10.1016/j.bbmt.2013.05.011

    Article  CAS  Google Scholar 

  5. Ratnasingam S, Walker PA, Tran H et al (2016) Bortezomib-based antibody depletion for refractory autoimmune hematological diseases. Blood Adv 1:31–35. https://doi.org/10.1182/bloodadvances.2016001412

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Jager U, Barcellini W, Broome CM et al (2019) Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting. Blood Rev 100648. https://doi.org/10.1016/j.blre.2019.100648

  7. Miao C, Junling Z (2017) A systematic review of low-dose rituximab in the treatment of warm autoimmune hemolytic anemia. Basic Clin Med 37(10):1444–1448

    Google Scholar 

  8. Muhsen IN, Alahmari A, Alnahedh M et al (2019) Bortezomib for immune thrombocytopenia and autoimmune hemolytic anemia. Hematol Oncol Stem Cell Ther. https://doi.org/10.1016/j.hemonc.2019.05.006

Download references

Funding

The work was supported by the National Natural Science Foundation of China (NSFC) (81970106) and the Beijing Natural Science Foundation (7192168).

Author information

Authors and Affiliations

Authors

Contributions

D.B.Z., B.H. and M.C. designed research. M. C, J.L.Z., J.L., C. Y, L. Z, W.W., H.C.C. and Y.F.Y. performed research. M.C. analyzed data and wrote the paper. B.H. revised the final draft. All authors reviewed and edited the final manuscript before submission.

Corresponding author

Correspondence to Bing Han.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Statement of ethics

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committee of Peking Union Medical College Hospital and with the 1964 Helsinki declaration and its later amendments.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, M., Zhuang, J., Yang, C. et al. Rapid response to a single-dose rituximab combined with bortezomib in refractory and relapsed warm autoimmune hemolytic anemia. Ann Hematol 99, 1141–1143 (2020). https://doi.org/10.1007/s00277-020-03976-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-020-03976-w

Navigation